Lazard Asset Management LLC decreased its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 59.9% during the first quarter, Holdings Channel reports. The firm owned 37,443 shares of the biotechnology company’s stock after selling 55,978 shares during the period. Lazard Asset Management LLC’s holdings in United Therapeutics Corporation were worth $5,069,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of UTHR. Norges Bank purchased a new stake in United Therapeutics Corporation during the fourth quarter valued at $63,975,000. Vanguard Group Inc. boosted its stake in United Therapeutics Corporation by 7.3% in the first quarter. Vanguard Group Inc. now owns 3,785,099 shares of the biotechnology company’s stock valued at $512,427,000 after buying an additional 256,514 shares during the period. BNP Paribas Arbitrage SA boosted its stake in United Therapeutics Corporation by 142.6% in the first quarter. BNP Paribas Arbitrage SA now owns 365,204 shares of the biotechnology company’s stock valued at $49,441,000 after buying an additional 214,687 shares during the period. Old Mutual Global Investors UK Ltd. boosted its stake in United Therapeutics Corporation by 32.7% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 820,823 shares of the biotechnology company’s stock valued at $111,123,000 after buying an additional 202,479 shares during the period. Finally, Cornerstone Capital Management Holdings LLC. boosted its stake in United Therapeutics Corporation by 362.0% in the first quarter. Cornerstone Capital Management Holdings LLC. now owns 204,177 shares of the biotechnology company’s stock valued at $27,640,000 after buying an additional 159,984 shares during the period.

Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Shares of United Therapeutics Corporation (NASDAQ:UTHR) traded up 0.45% on Monday, reaching $130.50. 157,421 shares of the company traded hands. The stock has a market capitalization of $5.88 billion, a P/E ratio of 9.16 and a beta of 1.56. The stock’s 50 day moving average price is $124.34 and its 200-day moving average price is $138.37. United Therapeutics Corporation has a one year low of $97.52 and a one year high of $169.89.

United Therapeutics Corporation (NASDAQ:UTHR) last announced its earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. United Therapeutics Corporation had a net margin of 41.04% and a return on equity of 34.74%. The firm had revenue of $370.50 million for the quarter, compared to analysts’ expectations of $399.59 million. During the same quarter in the previous year, the business posted $3.02 EPS. The company’s quarterly revenue was up .4% on a year-over-year basis. Equities analysts forecast that United Therapeutics Corporation will post $14.42 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Lazard Asset Management LLC Lowers Position in United Therapeutics Corporation (UTHR)” was originally reported by Watch List News and is the property of of Watch List News. If you are reading this piece on another domain, it was illegally stolen and republished in violation of US and international copyright legislation. The original version of this piece can be accessed at https://www.watchlistnews.com/lazard-asset-management-llc-lowers-position-in-united-therapeutics-corporation-uthr/1375440.html.

UTHR has been the subject of several recent analyst reports. Credit Suisse Group initiated coverage on shares of United Therapeutics Corporation in a research report on Thursday, March 16th. They set an “underperform” rating and a $120.00 price objective for the company. HC Wainwright reiterated a “hold” rating and set a $95.00 price objective on shares of United Therapeutics Corporation in a research report on Monday, April 17th. Cowen and Company cut shares of United Therapeutics Corporation from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $140.00 to $121.00 in a research report on Monday, April 3rd. Wedbush reiterated an “outperform” rating and set a $213.00 price objective (down from $229.00) on shares of United Therapeutics Corporation in a research report on Thursday, April 27th. Finally, Jefferies Group LLC reiterated a “sell” rating and set a $116.00 price objective on shares of United Therapeutics Corporation in a research report on Wednesday, April 12th. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and three have given a buy rating to the company’s stock. United Therapeutics Corporation presently has a consensus rating of “Hold” and an average target price of $137.09.

In other news, CEO Martine A. Rothblatt sold 1,238 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $130.20, for a total transaction of $161,187.60. Following the sale, the chief executive officer now owns 1,378 shares in the company, valued at approximately $179,415.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Tommy G. Thompson sold 2,000 shares of the business’s stock in a transaction on Wednesday, March 22nd. The shares were sold at an average price of $139.37, for a total transaction of $278,740.00. Following the sale, the director now owns 2,000 shares in the company, valued at approximately $278,740. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 18,258 shares of company stock worth $2,315,560. Company insiders own 7.50% of the company’s stock.

United Therapeutics Corporation Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR).

Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.